Sir Andrew Witty

CHAIRMAN

Sir Andrew Witty currently serves as Chairman of Hatteras Venture Partners.
 
Previously, Andrew has led two of the world’s largest healthcare companies during a 40-year career spanning the USA, Asia, Europe and Africa. Known as a champion of access to medicines and value-based care, he has implemented multiple innovations to help patients worldwide and overseen or contributed to the development of the world’s first vaccine for malaria and new medicines and vaccines in respiratory, anti-retroviral, anti-viral and cancer therapy. He also has extensive experience in consumer health, developing new products and modernizing the way individuals access healthcare. His advice has frequently been sought by policy makers around the world.
 
Andrew was Chief Executive Officer and Director of UnitedHealth Group from 2021 to 2025, after serving as Executive Vice President and Chief Executive Officer of Optum. From 2008 to 2017, he was Chief Executive Officer and Director of GlaxoSmithKline plc (GSK), which he joined in 1985, previously serving as President of GSK Europe.
 
Between April and December 2020, he took unpaid leave as Special Envoy at the World Health Organization, co-leading efforts to accelerate the development of and access to therapeutic, vaccine and diagnostic responses to COVID-19. In the United Kingdom, Andrew served on the Advisory Councils of Prime Ministers Brown and Cameron and as Lead Non-Executive Director for the Department of Business. Sir Andrew was knighted in 2012 for services to the U.K. economy and pharmaceutical industry and named an Honorary Citizen by Singapore in 2017 for his contributions to the country’s growth and development.
 
Andrew is a former Chancellor of the University of Nottingham and serves on the Singapore Prime Minister’s Research, Innovation and Enterprise Council. He holds Honorary Degrees from Exeter, Manchester and Nottingham Universities.